Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19
Antibody-dependent enhancement (ADE) has been shown previously for SARS-CoV-1, MERS-CoV, and SARS-CoV-2 infection in vitro. In this study, the first monoclonal antibody (mAb) that causes ADE in a SARS-CoV-2 in vivo model was identified. mAb RS2 against the SARS-CoV-2 S-protein was developed using hy...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/13/10799 |
| _version_ | 1797591573615083520 |
|---|---|
| author | Andrey Matveev Oleg Pyankov Yana Khlusevich Olga Tyazhelkova Lyudmila Emelyanova Anna Timofeeva Andrey Shipovalov Anton Chechushkov Natalia Zaitseva Gleb Kudrov Gaukhar Yusubalieva Saule Yussubaliyeva Oxana Zhukova Vladimir Baklaushev Sergey Sedykh Galina Lifshits Artem Tikunov Nina Tikunova |
| author_facet | Andrey Matveev Oleg Pyankov Yana Khlusevich Olga Tyazhelkova Lyudmila Emelyanova Anna Timofeeva Andrey Shipovalov Anton Chechushkov Natalia Zaitseva Gleb Kudrov Gaukhar Yusubalieva Saule Yussubaliyeva Oxana Zhukova Vladimir Baklaushev Sergey Sedykh Galina Lifshits Artem Tikunov Nina Tikunova |
| author_sort | Andrey Matveev |
| collection | DOAJ |
| description | Antibody-dependent enhancement (ADE) has been shown previously for SARS-CoV-1, MERS-CoV, and SARS-CoV-2 infection in vitro. In this study, the first monoclonal antibody (mAb) that causes ADE in a SARS-CoV-2 in vivo model was identified. mAb RS2 against the SARS-CoV-2 S-protein was developed using hybridoma technology. mAb RS2 demonstrated sub-nanomolar affinity and ability to neutralize SARS-CoV-2 infection in vitro with IC<sub>50</sub> 360 ng/mL. In an animal model of SARS-CoV-2 infection, the dose-dependent protective efficacy of mAb RS2 was revealed. However, in post-exposure prophylaxis, the administration of mAb RS2 led to an increase in the viral load in the respiratory tract of animals. Three groups of blood plasma were examined for antibodies competing with mAb RS2: (1) plasmas from vaccinated donors without COVID-19; (2) plasmas from volunteers with mild symptoms of COVID-19; (3) plasmas from patients with severe COVID-19. It was demonstrated that antibodies competing with mAb RS2 were significantly more often recorded in sera from volunteers with severe COVID-19. The results demonstrated for the first time that in animals, SARS-CoV-2 can induce antibody/antibodies that can elicit ADE. Moreover, in the sera of patients with severe COVID-19, there are antibodies competing for the binding of an epitope that is recognized by the ADE-eliciting mAb. |
| first_indexed | 2024-03-11T01:39:17Z |
| format | Article |
| id | doaj.art-a78a099836eb43d1a87dd01f600a6765 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T01:39:17Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a78a099836eb43d1a87dd01f600a67652023-11-18T16:43:47ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-06-0124131079910.3390/ijms241310799Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19Andrey Matveev0Oleg Pyankov1Yana Khlusevich2Olga Tyazhelkova3Lyudmila Emelyanova4Anna Timofeeva5Andrey Shipovalov6Anton Chechushkov7Natalia Zaitseva8Gleb Kudrov9Gaukhar Yusubalieva10Saule Yussubaliyeva11Oxana Zhukova12Vladimir Baklaushev13Sergey Sedykh14Galina Lifshits15Artem Tikunov16Nina Tikunova17Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaState Research Center of Virology and Biotechnology “VECTOR”, Rospotrebnadzor, 630559 Koltsovo, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaState Research Center of Virology and Biotechnology “VECTOR”, Rospotrebnadzor, 630559 Koltsovo, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaLaboratory of Molecular Epidemiology and Biodiversity of Viruses, Research Institute of Virology, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, RussiaState Research Center of Virology and Biotechnology “VECTOR”, Rospotrebnadzor, 630559 Koltsovo, RussiaFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, RussiaDepartment of General Medical Practice with the Course of Evidence-Based Medicine, Astana Medical University, Nur-Sultan 010000, KazakhstanFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, RussiaFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, RussiaFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, RussiaAntibody-dependent enhancement (ADE) has been shown previously for SARS-CoV-1, MERS-CoV, and SARS-CoV-2 infection in vitro. In this study, the first monoclonal antibody (mAb) that causes ADE in a SARS-CoV-2 in vivo model was identified. mAb RS2 against the SARS-CoV-2 S-protein was developed using hybridoma technology. mAb RS2 demonstrated sub-nanomolar affinity and ability to neutralize SARS-CoV-2 infection in vitro with IC<sub>50</sub> 360 ng/mL. In an animal model of SARS-CoV-2 infection, the dose-dependent protective efficacy of mAb RS2 was revealed. However, in post-exposure prophylaxis, the administration of mAb RS2 led to an increase in the viral load in the respiratory tract of animals. Three groups of blood plasma were examined for antibodies competing with mAb RS2: (1) plasmas from vaccinated donors without COVID-19; (2) plasmas from volunteers with mild symptoms of COVID-19; (3) plasmas from patients with severe COVID-19. It was demonstrated that antibodies competing with mAb RS2 were significantly more often recorded in sera from volunteers with severe COVID-19. The results demonstrated for the first time that in animals, SARS-CoV-2 can induce antibody/antibodies that can elicit ADE. Moreover, in the sera of patients with severe COVID-19, there are antibodies competing for the binding of an epitope that is recognized by the ADE-eliciting mAb.https://www.mdpi.com/1422-0067/24/13/10799COVID-19SARS-CoV-2antibody-dependent enhancementmonoclonal antibodyvirus neutralizing antibodyADE |
| spellingShingle | Andrey Matveev Oleg Pyankov Yana Khlusevich Olga Tyazhelkova Lyudmila Emelyanova Anna Timofeeva Andrey Shipovalov Anton Chechushkov Natalia Zaitseva Gleb Kudrov Gaukhar Yusubalieva Saule Yussubaliyeva Oxana Zhukova Vladimir Baklaushev Sergey Sedykh Galina Lifshits Artem Tikunov Nina Tikunova Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 International Journal of Molecular Sciences COVID-19 SARS-CoV-2 antibody-dependent enhancement monoclonal antibody virus neutralizing antibody ADE |
| title | Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 |
| title_full | Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 |
| title_fullStr | Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 |
| title_full_unstemmed | Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 |
| title_short | Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19 |
| title_sort | antibodies capable of enhancing sars cov 2 infection can circulate in patients with severe covid 19 |
| topic | COVID-19 SARS-CoV-2 antibody-dependent enhancement monoclonal antibody virus neutralizing antibody ADE |
| url | https://www.mdpi.com/1422-0067/24/13/10799 |
| work_keys_str_mv | AT andreymatveev antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT olegpyankov antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT yanakhlusevich antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT olgatyazhelkova antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT lyudmilaemelyanova antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT annatimofeeva antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT andreyshipovalov antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT antonchechushkov antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT nataliazaitseva antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT glebkudrov antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT gaukharyusubalieva antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT sauleyussubaliyeva antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT oxanazhukova antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT vladimirbaklaushev antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT sergeysedykh antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT galinalifshits antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT artemtikunov antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 AT ninatikunova antibodiescapableofenhancingsarscov2infectioncancirculateinpatientswithseverecovid19 |